A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CAI / clinical activity index

[Related PubMed/MEDLINE]
Total Number of Papers: 100
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CAI  (>> Co-occurring Abbreviation)
Long Form:   clinical activity index
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Efficacy and Safety of Adsorptive Granulocyte and Monocyte Apheresis in Elderly and Pregnant Patients with Ulcerative Colitis. GMA, UC
2019 Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis. 5-ASA, UC
2018 A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1year after leukocytapheresis. LCAP, UC
2018 Effect of fermented vegetable beverage containing Pediococcus pentosaceus in patients with mild to moderate ulcerative colitis. GSRS, UC
2018 Efficacy of cytapheresis for remission induction and dermatological manifestations of ulcerative colitis. EN, GMA, PG, TNF, UC
2018 Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission. MES, UC, UCEIS
2018 Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. GMA, ISs, UC
2018 Relationship between physician-based assessment of disease activity, quality of life, and costs of ulcerative colitis in Poland. UC
2017 Elevated levels of IL-2 and IL-21 produced by CD4+ T cells in inflammatory bowel disease. CD, HC, IBD, IL, PBMCs, UC
10  2017 Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. CRP, ELISA, IBD, LRG, MH, UC
11  2017 Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative Colitis. CAP, LI-CAP, UC
12  2017 Tacrolimus versus anti-tumor necrosis factor agents for steroid-refractory active ulcerative colitis based on the severity of endoscopic findings: a single-center, open-label cohort study. TAC, TNF, UC, UCEIS
13  2017 Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. FC, MH, PMS, UC
14  2016 Achilles tendinitis as a rare extraintestinal manifestation of ulcerative colitis. EIMs
15  2016 Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. DIMS0150, TLRs, UC
16  2016 Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial. CAL, CRP, DAI, EI, FLA, PMN-E, RR, UC, WBC
17  2016 First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. IFX, TL, UC
18  2015 Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy. ANN, CAP, UC
19  2015 Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis. GMA, UC
20  2015 Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. UC
21  2015 Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. GMA, IBDQ, UC
22  2015 Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis. ---
23  2015 Usefulness of selected laboratory markers in ulcerative colitis. IL, UC
24  2014 Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study. IBS, UC
25  2014 Therapeutic efficacy of pH-dependent release formulation of mesalazine on active ulcerative colitis resistant to time-dependent release formulation: analysis of fecal calprotectin concentration. MH, UC
26  2013 Calcitonin gene-related peptide is a promising marker in ulcerative colitis. CGRP, EAI, RT-PCR
27  2013 Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. GMA, PSL, UC
28  2013 Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study. CD, CDAI, GCAP, IBD, SD, SR, UC
29  2013 Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. CAP, UC
30  2013 Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. SS, UC
31  2013 Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. GMA, PSL, ROC, UC, WBC
32  2013 Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis. UC
33  2013 Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. GMA, PSL, TNF, UC
34  2012 Curcumin for maintenance of remission in ulcerative colitis. EI, MD, RCT, RR, UC
35  2012 Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. BW, EI, GMA, UC
36  2012 Readministration of calcineurin inhibitors for ulcerative colitis. CNIs, UC
37  2011 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. EI, OD, UC
38  2011 A multicenter study of the efficacy and safety of leukocytapheresis therapy without concomitant systemic steroid treatment in patients with active ulcerative colitis. LCAP, UC
39  2011 Gender related differences in quality of life and affective status in patients with inflammatory bowel disease. CDAI, HRQoL, IBD, IBDQoL
40  2011 Images of colonic real-time tissue sonoelastography correlate with those of colonoscopy and may predict response to therapy in patients with ulcerative colitis. UC
41  2011 Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis. CI, CRP, ESR, GMA, OR
42  2011 Relevance of the processed blood volume per granulocyte and monocyte apheresis session to its clinical efficacy in patients with ulcerative colitis. BW, GMA, PV, UC
43  2011 The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. CDAI, GMA
44  2010 Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. GM, UC
45  2010 Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis. EI, HS, PP, UC
46  2010 Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. EAI, rPC
47  2010 Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases. UC
48  2010 Phosphatidylcholine (lecithin) and the mucus layer: Evidence of therapeutic efficacy in ulcerative colitis? CD, PC, rPC, UC
49  2010 Validity of activity indices in ulcerative colitis: comparison of clinical and endoscopic indices. CI, DAI, LI, REI, UC
50  2010 [Fecal excretion of short-chain fatty acids as a marker of the severity of ulcerative colitis]. EAI, SCFA, UC
51  2009 Cytapheresis in patients with severe ulcerative colitis after failure of intravenous corticosteroid: a long-term retrospective cohort study. CAP, UC
52  2009 Interleukin-18 serum levels in inflammatory bowel diseases: correlation with disease activity and inflammatory markers. CD, CDAI, CRP, IBD, IL-18, UC
53  2009 Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. ITT, OD, PP, TID
54  2009 Predicting the clinical response to cytapheresis in steroid-refractory or -dependent ulcerative colitis using contrast-enhanced ultrasonography. CEUS, CRP, GCAP, LCAP, PDUS, UC, US
55  2009 The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease. FoxP3, GMA, HC, UC
56  2009 Transcript levels of different cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitis. EAI, UC
57  2008 A multi center study of granulocyte and monocyte adsorption apheresis therapy for ulcerative colitis-clinical efficacy and production of interleukin-1 receptor antagonist. GCAP, GMs, IL-1ra
58  2008 Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. CD, CDAI, FISH, IBD, UC
59  2008 Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study. GMCAP, LCAP, UC
60  2008 Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis. CRP, LCAP, UC
61  2008 Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. ITT, PP, UC
62  2008 Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study. LCAP, UC
63  2008 Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. DAI, IBD, LMWHs, UC
64  2007 Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. GMA, IL-8, TLRs, UC
65  2007 Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. ---
66  2007 Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. ---
67  2007 Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial. nIFN-beta, UC
68  2007 Tormentil for active ulcerative colitis: an open-label, dose-escalating study. LC-MS, TE, UC
69  2006 Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients. EI, LCAP, NG, RG, UC
70  2006 Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. EI, SZ, UC
71  2006 Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis. GMA, UC
72  2006 Health-related quality of life correlates with clinical and endoscopic activity indexes but not with demographic features in patients with ulcerative colitis. EAI, HRQoL, IBD, IBDQ-D, UC
73  2006 Increased circulating platelet-neutrophil, platelet-monocyte complexes, and platelet activation in patients with ulcerative colitis: a comparative study. EAI, PMC, PMP, PNC, TAT, UC
74  2006 Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study. CD, CDAI, EI, GCAP, IBD, UC
75  2005 Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. LCAP, UC
76  2005 Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. CD, CDAI, ELISA, IBD, PDMPs, sP-selectin, UC
77  2005 How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? AI, CD, CDAI, HBI, IBD, RCV, SD, SNR, UC
78  2005 Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. rIFN-beta-1a
79  2005 Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. LCAP, UC
80  2005 Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. EAI
81  2004 Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. GMA, PSL, SD, UC
82  2004 Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. GMA
83  2004 Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. GBF, UC
84  2004 Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. GM, GMA, PB, UC
85  2004 Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. UC
86  2003 Effect of ulcerative colitis treatment on transforming growth factor beta(1) in plasma and rectal mucosa. DAI, UC
87  2003 Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. DAI, GM, UC
88  2003 The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. EI
89  2002 Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. CDAI, EQ VAS, IBDQ
90  2001 Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. 5-ASA
91  2001 Serum transglutaminase correlates with endoscopic and histopathologic grading in patients with ulcerative colitis. MPO, UC
92  2001 The prognostic value, in active ulcerative colitis, of an increased intensity of colonic perivisceral fat signal on magnetic resonance imaging with ferumoxil. MRI, PFSI, UC
93  2001 [Efficacy of mesalamine enema in the treatment of steroid-resistant or dependent distal ulcerative colitis]. ---
94  2000 Sonographic measurement of thickened bowel wall segments as a quantitative parameter for activity in inflammatory bowel disease. CD, CDAI, CDAI, CAI, CRP, ESR, IBD, UC, US, VIB
95  2000 [Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study]. EI, HI
96  1999 Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis. AAT, CD, CDAI, IBD, UC
97  1997 Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. ---
98  1997 Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial. c-GCS
99  1996 Relationship between the use of unconventional therapies and disease-related concerns: a study of patients with inflammatory bowel disease. CDAI, IBD, RFIPC
100  1989 Health status and disease activity in systemic lupus erythematosus. AIMS, SLE